These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 26281685)

  • 1. [Kinase inhibitors and their resistance].
    Togashi Y; Nishio K
    Nihon Rinsho; 2015 Aug; 73(8):1323-9. PubMed ID: 26281685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting receptor tyrosine kinases in solid tumors.
    Zhang J; Hochwald SN
    Surg Oncol Clin N Am; 2013 Oct; 22(4):685-703. PubMed ID: 24012395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dissecting kinase signaling pathways.
    Boyle SN; Koleske AJ
    Drug Discov Today; 2007 Sep; 12(17-18):717-24. PubMed ID: 17826684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Molecular targeted drugs for soft tissue sarcoma and neuroendocrine tumor].
    Kato S
    Nihon Rinsho; 2015 Aug; 73(8):1398-402. PubMed ID: 26281696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cutaneous side effects associated with epidermal growth factor receptor and tyrosine kinase inhibitors].
    Deslandres M; Sibaud V; Chevreau C; Delord JP
    Ann Dermatol Venereol; 2008 Jan; Spec No 1():16-24. PubMed ID: 18342113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Antineoplastic agents targeting tyrosine kinases].
    Guren TK; Christoffersen T; Thoresen GH; Wisløff F; Dajani O; Tveit KM
    Tidsskr Nor Laegeforen; 2005 Nov; 125(22):3115-9. PubMed ID: 16299568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein kinases as drug targets in cancer.
    Arslan MA; Kutuk O; Basaga H
    Curr Cancer Drug Targets; 2006 Nov; 6(7):623-34. PubMed ID: 17100568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.
    Agostino NM; Chinchilli VM; Lynch CJ; Koszyk-Szewczyk A; Gingrich R; Sivik J; Drabick JJ
    J Oncol Pharm Pract; 2011 Sep; 17(3):197-202. PubMed ID: 20685771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Kinase inhibitors].
    Yamori T; Kong D
    Nihon Rinsho; 2010 Jun; 68(6):1059-66. PubMed ID: 20535956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapeutic agents and the skin: An update.
    Heidary N; Naik H; Burgin S
    J Am Acad Dermatol; 2008 Apr; 58(4):545-70. PubMed ID: 18342708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Molecular targeted therapy for malignant brain tumors].
    Okamura T; Kurisu K
    Nihon Rinsho; 2005 Sep; 63 Suppl 9():520-6. PubMed ID: 16201575
    [No Abstract]   [Full Text] [Related]  

  • 12. [The use of targeted therapies in oncology and their impact in the design of clinical trials: epidermal growth factor receptors 1 and 2 as a paradigm].
    Dalmases A; Rojo F; Rovira A; Albanell J
    Med Clin (Barc); 2013 Aug; 141(4):176-80. PubMed ID: 23809407
    [No Abstract]   [Full Text] [Related]  

  • 13. [Management of hypothyroidism secondary to tyrosine kinase inhibitors: description of treatment in three distinct clinical settings].
    Pérez López G; Carrasco De La Fuente M; Menacho Román M; González Albarrán O; Cano Megías M
    Endocrinol Nutr; 2011 Feb; 58(2):94-6. PubMed ID: 21333617
    [No Abstract]   [Full Text] [Related]  

  • 14. Tyrosine kinase inhibitor-induced macrocytosis.
    Schallier D; Trullemans F; Fontaine C; Decoster L; De Greve J
    Anticancer Res; 2009 Dec; 29(12):5225-8. PubMed ID: 20044640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New possibilities of targeted therapy in the treatment of hepatocellular carcinoma with the help of molecular biology].
    Hagymási K; Tulassay Z
    Orv Hetil; 2010 Oct; 151(43):1763-8. PubMed ID: 20940115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of kinase inhibitors using different phosphorylation states of colony stimulating factor-1 receptor tyrosine kinase.
    Kitagawa D; Gouda M; Kirii Y; Sugiyama N; Ishihama Y; Fujii I; Narumi Y; Akita K; Yokota K
    J Biochem; 2012 Jan; 151(1):47-55. PubMed ID: 21880693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From genome to drugs: where do we stand?
    Schmidt C
    J Natl Cancer Inst; 2011 Jul; 103(13):996-7. PubMed ID: 21693728
    [No Abstract]   [Full Text] [Related]  

  • 18. [The mechanisms of the resistance to molecular targeting agents].
    Akiyama S
    Nihon Rinsho; 2004 Jul; 62(7):1297-304. PubMed ID: 15283147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Targeted drugs in radiation therapy].
    Favaudon V; Hennequin C
    Cancer Radiother; 2004 Nov; 8 Suppl 1():S114-20. PubMed ID: 15679256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Molecular target therapy for malignant tumors].
    Nihon Naika Gakkai Zasshi; 2005 Feb; 94 Suppl():76-80. PubMed ID: 15796061
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.